



**Recommendation to the Cancer Systemic Therapy Policy Committee (CSTPC)  
from Capital District Health Authority/Cancer Care Nova Scotia**

**Guidelines for the Role of Bortezomib in Multiple Myeloma (MM)**

**Approved Use:**

**Bortezomib:** In **combination with melphalan and prednisone (VMP)** for the treatment of patients with previously untreated MM who are not candidates for stem cell transplantation (SCT). This criteria is in addition to the previously approved indication as a single agent in the second line and beyond setting of refractory or relapsed MM following first or second line options such as SCT, high dose steroids, alkylator-based (i.e: melphelan and prednisone) or multiagent chemotherapy and choose to receive additional therapy.

- This policy recommendation represents an **expansion** of the existing criteria and a restriction of bortezomib to include the use of combination therapy (VMP) in patients with previously untreated MM who are not candidates for SCT.